Duchenne Muscular Dystrophy Drugs Market (2024 - 2030) Size, Share & Trends Analysis Report By Treatment (Molecular Based, Steroid Based, NSAIDs), By Distribution Channel, By Region, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation and Scope
                   1.2. Market Definitions
                   1.3. Research Methodology
                       1.3.1. Information Procurement
                       1.3.2. Information or Data Analysis
                       1.3.3. Market Formulation & Data Visualization
                       1.3.4. Data Validation & Publishing
                   1.4. Research Scope and Assumptions
                       1.4.1. List of Data Sources
Chapter 2. Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                   2.3. Competitive Insights
Chapter 3. Duchenne Muscular Dystrophy (DMD) Drugs Market Variables, Trends, & Scope
                   3.1. Market Introduction/Lineage Outlook
                   3.2. Market Size and Growth Prospects (USD Million)
                   3.3. Market Dynamics
                       3.3.1. Market Drivers Analysis
                       3.3.2. Market Restraints Analysis
                   3.4. Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis Tools
                       3.4.1. Porter’s Analysis
                           3.4.1.1. Bargaining Power of the Suppliers
                           3.4.1.2. Bargaining Power of the Buyers
                           3.4.1.3. Threats of Substitution
                           3.4.1.4. Threats From New Entrants
                           3.4.1.5. Competitive Rivalry
                       3.4.2. PESTEL Analysis
                           3.4.2.1. Political Landscape
                           3.4.2.2. Economic and Social Landscape
                           3.4.2.3. Technological Landscape
                           3.4.2.4. Environmental Landscape
                           3.4.2.5. Legal Landscape
Chapter 4. Duchenne Muscular Dystrophy (DMD) Drugs Market: Treatment Estimates & Trend Analysis
                   4.1. Segment Dashboard
                   4.2. Duchenne Muscular Dystrophy (DMD) Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
                   4.3. Molecular Based Therapies
                       4.3.1. Molecular Based Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                       4.3.2. Mutation Suppression
                           4.3.2.1. Mutation Suppression Composite Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                       4.3.3. Exon Suppression
                           4.3.3.1. Exon Suppression Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                   4.4. Steroid Based Therapies
                       4.4.1. Steroid Based Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                   4.5. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
                       4.5.1. Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                   4.6. Others
                       4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Duchenne Muscular Dystrophy (DMD) Drugs Market: Distribution Channel Estimates & Trend Analysis
                   5.1. Segment Dashboard
                   5.2. Duchenne Muscular Dystrophy (DMD) Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
                   5.3. Hospital Pharmacies
                       5.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                   5.4. Retail Pharmacies
                       5.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
                   5.5. Online Pharmacies
                       5.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Duchenne Muscular Dystrophy (DMD) Drugs Market: Regional Estimates & Trend Analysis
                   6.1. Duchenne Muscular Dystrophy (DMD) Drugs Market Share, By Region, 2023 & 2030, USD Million
                   6.2. North America
                       6.2.1. North America Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.2.2. U.S.
                           6.2.2.1. U.S. Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.2.3. Canada
                           6.2.3.1. Canada Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.2.4. Mexico
                           6.2.4.1. Mexico Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                   6.3. Europe
                       6.3.1. Europe Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.2. UK
                           6.3.2.1. UK Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.3. Germany
                           6.3.3.1. Germany Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.4. France
                           6.3.4.1. France Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.5. Italy
                           6.3.5.1. Italy Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.6. Spain
                           6.3.6.1. Spain Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.7. Denmark
                           6.3.7.1. Denmark Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.8. Sweden
                           6.3.8.1. Sweden Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.3.9. Norway
                           6.3.9.1. Norway Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                   6.4. Asia Pacific
                       6.4.1. Asia Pacific Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.4.2. Japan
                           6.4.2.1. Japan Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.4.3. China
                           6.4.3.1. China Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.4.4. India
                           6.4.4.1. India Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.4.5. Australia
                           6.4.5.1. Australia Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.4.6. South Korea
                           6.4.6.1. South Korea Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.4.7. Thailand
                           6.4.7.1. Thailand Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                   6.5. Latin America
                       6.5.1. Latin America Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.5.2. Brazil
                           6.5.2.1. Brazil Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.5.3. Argentina
                           6.5.3.1. Argentina Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                   6.6. Middle East and Africa
                       6.6.1. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.6.2. South Africa
                           6.6.2.1. South Africa Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.6.3. Saudi Arabia
                           6.6.3.1. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.6.4. UAE
                           6.6.4.1. UAE Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
                       6.6.5. Kuwait
                           6.6.5.1. Kuwait Duchenne Muscular Dystrophy (DMD) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Recent Developments & Impact Analysis by Key Market Participants
                   7.2. Company Categorization
                   7.3. Company Heat Map Analysis
                   7.4. Company Profiles
                       7.4.1. Aurobindo Pharma
                           7.4.1.1. Participant’s Overview
                           7.4.1.2. Financial Performance
                           7.4.1.3. Product Benchmarking
                           7.4.1.4. Recent Developments/ Strategic Initiatives
                       7.4.2. Capricor Therapeutics, Inc.
                           7.4.2.1. Participant’s Overview
                           7.4.2.2. Financial Performance
                           7.4.2.3. Product Benchmarking
                           7.4.2.4. Recent Developments/ Strategic Initiatives
                       7.4.3. Catalyst Pharmaceuticals, Inc.
                           7.4.3.1. Participant’s Overview
                           7.4.3.2. Financial Performance
                           7.4.3.3. Product Benchmarking
                           7.4.3.4. Recent Developments/ Strategic Initiatives
                       7.4.4. EspeRare Foundation
                           7.4.4.1. Participant’s Overview
                           7.4.4.2. Financial Performance
                           7.4.4.3. Product Benchmarking
                           7.4.4.4. Recent Developments/ Strategic Initiatives
                       7.4.5. FibroGen, Inc.
                           7.4.5.1. Participant’s Overview
                           7.4.5.2. Financial Performance
                           7.4.5.3. Product Benchmarking
                           7.4.5.4. Recent Developments/ Strategic Initiatives
                       7.4.6. ITALFARMACO S.p.A.
                           7.4.6.1. Participant’s Overview
                           7.4.6.2. Financial Performance
                           7.4.6.3. Product Benchmarking
                           7.4.6.4. Recent Developments/ Strategic Initiatives
                       7.4.7. NS Pharma, INC.
                           7.4.7.1. Participant’s Overview
                           7.4.7.2. Financial Performance
                           7.4.7.3. Product Benchmarking
                           7.4.7.4. Recent Developments/ Strategic Initiatives
                       7.4.8. PTC Therapeutics.
                           7.4.8.1. Participant’s Overview
                           7.4.8.2. Financial Performance
                           7.4.8.3. Product Benchmarking
                           7.4.8.4. Recent Developments/ Strategic Initiatives
                       7.4.9. Santhera Pharmaceuticals
                           7.4.9.1. Participant’s Overview
                           7.4.9.2. Financial Performance
                           7.4.9.3. Product Benchmarking
                           7.4.9.4. Recent Developments/ Strategic Initiatives
                       7.4.10. Sarepta Therapeutics, Inc.
                           7.4.10.1. Participant’s Overview
                           7.4.10.2. Financial Performance
                           7.4.10.3. Product Benchmarking
                           7.4.10.4. Recent Developments/ Strategic Initiatives